Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

• Johnson DB Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.
• Menzies AM Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
• Zimmer L Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany.
• Eroglu Z Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
• Ye F Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• Zhao S Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• Rizos H Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Macquarie University, Sydney, NSW, Australia.
• Sucker A Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany.
• Scolyer RA Melanoma Institute Australia, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
• Gutzmer R Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
• Gogas H First Department of Medicine, University of Athens Medical School, Athens, Greece.
• Kefford RF Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Macquarie University, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
• Thompson JF Melanoma Institute Australia, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
• Becker JC Translational Skin Cancer Research, German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
• Berking C Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany.
• Egberts F Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
• Loquai C Department of Dermatology, University Medical Center, Mainz, Germany.
• Goldinger SM Department of Dermatology, University Hospital Zürich, Switzerland.
• Pupo GM Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia.
• Hugo W Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
• Kong X Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
• Garraway LA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
• Sosman JA Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• Ribas A Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
• Lo RS Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
• Long GV Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
• Schadendorf D Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany.

Show more…

Acquired

BRAF

Dabrafenib

MAPK

MEK1

Meta-analysis

NRAS

Resistance

Splice

Vemurafenib

Antineoplastic Agents

Australia

Biomarkers, Tumor

DNA Mutational Analysis

Disease Progression

Disease-Free Survival

Drug Resistance, Neoplasm

Europe

Female

Genetic Predisposition to Disease

Humans

Kaplan-Meier Estimate

Male

Melanoma

Middle Aged

Mutation

Phenotype

Proportional Hazards Models

Protein Kinase Inhibitors

Proto-Oncogene Proteins B-raf

Risk Factors

Signal Transduction

Skin Neoplasms

Time Factors

Treatment Outcome

United States